Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium.
Roxana Mehran, Sunil V Rao, Deepak L Bhatt...
https://pubmed.ncbi.nlm.nih.gov/21670242/Actively Recruiting
Led by CHA University · Updated on 2026-02-18
490
Participants Needed
9
Research Sites
N/A
Total Duration
Researchers are studying patients with acute coronary syndrome ACS who have undergone percutaneous coronary intervention PCI to evaluate the effects of a treatment combining ticagrelor P2Y12 inhibitor monotherapy with low-dose colchicine. This study aims to determine how often serious cardiovascular events and stent thrombosis occur within 12 months after PCI when aspirin is discontinued and replaced by colchicine alongside ticagrelor. The research will also compare this approach to different durations of dual antiplatelet therapy from previous studies to assess its effectiveness and safety. Participants will take low-dose colchicine 0.6 mg once daily with ticagrelor maintenance therapy 90 mg twice daily after PCI, stopping aspirin the day after the procedure. One month following PCI, a high-sensitivity C-reactive protein hs-CRP test will be conducted colchicine will be stopped if hs-CRP is below 2 mgL or continued for 12 months if it is 2 mgL or higher. Patients will have scheduled clinic visits at 1, 3, 6, 9, and 12 months post-PCI for follow-up. During the study, participants will undergo regular check-ups including hs-CRP testing and monitoring for cardiovascular events, stent thrombosis, bleeding, inflammation, platelet activity, and drug reactions to colchicine. Researchers will track these outcomes at multiple time points up to 12 months to assess the treatments clinical effects and safety. The total participation period spans one year after the PCI intervention.
CONDITIONS
MACT (Mono Antiplatelet and Colchicine Therapy) Prospective Multicenter Study
H
Hwa-In Kim
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
CHA University
Lead Sponsor
Biotronik SE & Co. KG
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 12 months after PCI
Participants take low-dose colchicine (0.6 mg once daily) in addition to ticagrelor maintenance therapy and discontinue aspirin the day after PCI. Colchicine is continued based on hs-CRP test results at 1 month.
Visits at 1 month, 3 months, 6 months, 9 months, and 12 months post-PCI
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Have more questions? Get in touch with our team for quick support
Roxana Mehran, Sunil V Rao, Deepak L Bhatt...
https://pubmed.ncbi.nlm.nih.gov/21670242/Seung-Yul Lee, Jae Young Cho, Diana A Gorog...
https://pubmed.ncbi.nlm.nih.gov/38841588/Donald E Cutlip, Stephan Windecker, Roxana Mehran...
https://pubmed.ncbi.nlm.nih.gov/17470709/Byeong-Keuk Kim, Sung-Jin Hong, Yun-Hyeong Cho...
https://pubmed.ncbi.nlm.nih.gov/32543684/Sung-Jin Hong, Seung-Jun Lee, Yongsung Suh...
https://pubmed.ncbi.nlm.nih.gov/37878786/Ji Yong Jang, Yongsung Suh, Choongki Kim...
https://pubmed.ncbi.nlm.nih.gov/41221450/Seung-Yul Lee, Young-Hoon Jeong, Kyeong Ho Yun...
https://pubmed.ncbi.nlm.nih.gov/37587591/CHA University
Lead Sponsor
Biotronik SE & Co. KG
Collaborating Sponsor